This is the authors' abstract. We don't add key points for this paper.
Vitiligo is a chronic immune-mediated skin disorder that can affect a patient's psychological well-being, quality of life, and social acceptance. It is characterized by depigmented white patches and macules due to the targeted destruction of melanocytes - which are responsible for giving color to the skin. The exact cause is unknown, but it is believed to be triggered by an auto-immune response, genetic factors, and stress. With a worldwide prevalence of 0.5–2% [1], vitiligo can be treated with phototherapy, involving exposure to ultraviolet light; topical steroids, and immunosuppressant drugs like calcineurin inhibitors and monoisotopic peptide receptor antagonists; excisional treatments like surgery or lasers; and various combinations of these techniques that help in slowing down the progression of the disease. However, the side effects of these treatments, particularly skin cancer, can be concerning. Ruxolitinib, a Janus kinase (JAK) inhibitor, has recently received U.S. Food and Drug Administration (FDA) approval as a first-of-its-kind treatment for non-segmental vitiligo, the most common form of the condition [2]. The drug selectively targets JAK1 and JAK2 receptors to decrease interferon gamma signaling by T cells, dendritic cells, and macrophages in response to pathogens. It also decreases interleukin-2 (IL-2) cytokine levels that trigger the immune response against melanocytes. This can halt the destruction of these cells, leading to skin repigmentation in patients with vitiligo [3]. The approval came after groundbreaking results from a phase 3 open-label study; TRuE-V showed more than 75% improvement in facial vitiligo area scoring index (F-VASI75) and more than 50% improvement in total body VASI (T-VASI50) as compared to the control group. This trial was conducted in the United States and Canada to evaluate the safety and efficacy of Ruxolitinib cream when applied twice a day topically for 24 weeks in patients with non-segmental vitiligo. Clinics were assessed for repigmentation of the vitiligo patches at baseline and weeks 4, 8, 12, and 24. The study found that the skin pigmentation significantly increased from baseline after four weeks of treatment. Few common side effects were reported, such as redness, itchiness, application-site acne, headache, urinary tract infection, and fever [4,5]. Opzelura (ruxolitinib) topical cream, manufactured by Incyte, was previously approved by FDA for 12 years of age or older patients without impaired immunity suffering from mild to moderate atopic dermatitis [6]. For non-segmental vitiligo, Opzelura is the first ever topical remedy working on skin repigmentation to receive FDA approval. As per Incyte, it can take more than five months in patients 12 and older to show expected results by applying it to the affected areas twice daily. However, the manufacturer does not recommend combination therapy with other JAK inhibitors or immunosuppressants [7]. The findings from this clinical trial and approval by FDA have provided hope to patients suffering from vitiligo. This can markedly decrease psychological stress and improve their quality of life. The drug can also help reduce the frequency of phototherapy sessions and its associated adverse outcomes. With only mild side effects, it is expected to be widely prescribed for vitiligo patients. One of this drug's significant drawbacks is its cost, as Opzelura retails at around 2000 USD per tube, which might be a concern for patients, especially from developing countries [8]. Hence, the drug's pricing should be regulated and accessible for patients from low socio-economic regions. Dosing must be done according to the prescribed schedule to avoid unnecessary consequences. Opzelura should be used with caution in patients suffering from life-threatening conditions such as cardiovascular disorders, malignancies, and diabetes until more data is available. Lastly, future trials should be carried out to assess the long-term side effects of topical JAK inhibitors. Hopefully, these groundbreaking studies will lead to the development of more novel and efficient treatments for other immune-mediated skin disorders such as psoriasis, hidradenitis suppurativa, and alopecia areata. Ethical approval Not applicable. Please state any sources of funding for your research The authors received no extramural funding for the study.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Siddiq et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: